AU2006343439B2 - The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with a-MSH administered in prophylactic or therapeutic form - Google Patents

The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with a-MSH administered in prophylactic or therapeutic form Download PDF

Info

Publication number
AU2006343439B2
AU2006343439B2 AU2006343439A AU2006343439A AU2006343439B2 AU 2006343439 B2 AU2006343439 B2 AU 2006343439B2 AU 2006343439 A AU2006343439 A AU 2006343439A AU 2006343439 A AU2006343439 A AU 2006343439A AU 2006343439 B2 AU2006343439 B2 AU 2006343439B2
Authority
AU
Australia
Prior art keywords
msh
pharmaceutical composition
nicotine
approximately
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006343439A
Other languages
English (en)
Other versions
AU2006343439A1 (en
Inventor
Arturo Solis Herrera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006343439(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of AU2006343439A1 publication Critical patent/AU2006343439A1/en
Application granted granted Critical
Publication of AU2006343439B2 publication Critical patent/AU2006343439B2/en
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2006343439A 2006-05-08 2006-05-08 The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with a-MSH administered in prophylactic or therapeutic form Active AU2006343439B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2006/000031 WO2007129879A1 (es) 2006-05-08 2006-05-08 EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA.

Publications (2)

Publication Number Publication Date
AU2006343439A1 AU2006343439A1 (en) 2007-11-15
AU2006343439B2 true AU2006343439B2 (en) 2013-05-16

Family

ID=38667940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006343439A Active AU2006343439B2 (en) 2006-05-08 2006-05-08 The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with a-MSH administered in prophylactic or therapeutic form

Country Status (13)

Country Link
US (4) US20090197921A1 (https=)
EP (4) EP2801359A3 (https=)
JP (1) JP2009536193A (https=)
KR (1) KR20130116374A (https=)
CN (1) CN101437515B (https=)
AU (1) AU2006343439B2 (https=)
BR (1) BRPI0621650A2 (https=)
CA (1) CA2651580C (https=)
DK (1) DK2801360T3 (https=)
ES (1) ES2683323T3 (https=)
MX (1) MX2008011473A (https=)
NZ (1) NZ572366A (https=)
WO (1) WO2007129879A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20110206642A1 (en) * 2009-10-15 2011-08-25 Cohava Gelber Preventing obesity-related metabolic syndrome with melagonesis
MX369060B (es) 2014-09-09 2019-10-28 Solis Herrera Arturo Métodos para tratar y prevenir enfermedades, trastornos, y condiciones oculares con melanina y análogos de melanina, precursores y derivados.
EP3442583B1 (en) 2016-04-12 2024-04-10 Arturo Solis Herrera Composition comprising nicotine for treating bleeding of the nasal or paranasal mucosa
LU101520B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282906A1 (en) * 2004-03-25 2005-12-22 North Shore-Long Island Jewish Research Institute Neural tourniquet

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282906A1 (en) * 2004-03-25 2005-12-22 North Shore-Long Island Jewish Research Institute Neural tourniquet

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTY, M. A. ET AL Pharmacology Biochemistry and Behaviour (1995), 22: 317-325 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE
US9918996B2 (en) 2012-02-22 2018-03-20 Arturo Solis Herrera Methods of using qiapine

Also Published As

Publication number Publication date
JP2009536193A (ja) 2009-10-08
DK2801360T3 (en) 2018-07-23
US20090197921A1 (en) 2009-08-06
CN101437515A (zh) 2009-05-20
EP2801358A2 (en) 2014-11-12
US20120270907A1 (en) 2012-10-25
CN101437515B (zh) 2016-04-20
MX2008011473A (es) 2008-09-24
EP2027860A1 (en) 2009-02-25
CA2651580A1 (en) 2007-11-15
AU2006343439A1 (en) 2007-11-15
EP2801360A3 (en) 2015-03-04
EP2801360B1 (en) 2018-04-25
EP2801359A3 (en) 2015-05-06
CA2651580C (en) 2016-01-19
BRPI0621650A2 (pt) 2011-12-20
EP2801359A2 (en) 2014-11-12
NZ572366A (en) 2012-02-24
US20160279116A1 (en) 2016-09-29
WO2007129879A1 (es) 2007-11-15
EP2801358A3 (en) 2015-03-04
EP2801360A2 (en) 2014-11-12
US20160008347A1 (en) 2016-01-14
KR20130116374A (ko) 2013-10-23
ES2683323T3 (es) 2018-09-26

Similar Documents

Publication Publication Date Title
US20160279116A1 (en) Therapeutic uses of nicotine
CN103893211A (zh) 包含人胚胎干细胞和其衍生物的组合物、其使用方法和制备方法
US20120232142A1 (en) Novel use of dimethylfumarate
CN113577083B (zh) 一种小分子化合物组合在制备预防和治疗视网膜损伤性疾病药物中的应用
Goyagi et al. Neuroprotective effects of selective beta-1 adrenoceptor antagonists, landiolol and esmolol, on transient forebrain ischemia in rats; a dose–response study
CN116098918B (zh) 一种胞磷胆碱药物组合物及其用途
JPH03135918A (ja) 免疫賦活剤
RU2442584C2 (ru) ИСПОЛЬЗОВАНИЕ НИКОТИНА, ЕГО АНАЛОГОВ, ПРЕДШЕСТВЕННИКОВ И ПРОИЗВОДНЫХ ПРИ ЛЕЧЕНИИ РАЗЛИЧНЫХ ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ, ПОДДАЮЩИХСЯ ЛЕЧЕНИЮ, ПУТЕМ ВВЕДЕНИЯ α-MSH ДЛЯ ПРОФИЛАКТИЧЕСКИХ ИЛИ ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ
Walter Clinical impressions on treatment of obsessional states with intravenous clomipramine (Anafranil)
CN119792487B (zh) 一种预防和治疗缺血性脑卒中的药物
KR20090006069A (ko) 예방적 또는 치료적 형태로 투여된 α-ＭＳＨ를 사용하여 개선시킬 수 있는 다양한 병리 과정을 치료하기 위한 니코틴, 그의 유사체, 그의 전구체 또는 그의 유도체의 용도
CN117224514B (zh) 一种化合物、组合物及其在制备治疗心律失常的药物中的应用
CN115192712B (zh) Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用
WO2025256277A1 (zh) 黑素细胞刺激素α-MSH在治疗肝癌中的应用
WO2019169712A1 (zh) 丁酸类化合物在促进组织内源性干细胞活化、增殖和分化中的应用
ES2748475T3 (es) Composiciones que comprenden células madre embrionarias humanas y sus derivados, procedimientos de uso y procedimientos de preparación
CN106860444A (zh) 3,4,7‑三羟基异黄酮或3‑甲氧基大豆素在制备抑制炎症和脑缺血药物的应用
TW200418493A (en) Neovascularization promoting agent
JPH01502666A (ja) 閉塞性気道疾患の治療のための製剤
CN110731957A (zh) 表没食子儿茶素没食子酸酯在制备治疗血管疾病药物中的用途
JPS61275225A (ja) 抗炎症剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)